230 related articles for article (PubMed ID: 14716146)
21. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab in the treatment of patients with colorectal cancer.
Garrett CR; Eng C
Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
[TBL] [Abstract][Full Text] [Related]
24. Critical evaluation of current treatments in metastatic colorectal cancer.
Venook A
Oncologist; 2005 Apr; 10(4):250-61. PubMed ID: 15821245
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab in previously treated colorectal cancer.
Starling N; Cunningham D
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S28-33. PubMed ID: 15871763
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
27. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
28. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
[TBL] [Abstract][Full Text] [Related]
29. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
Vincenzi B; Santini D; Russo A; Gavasci M; Battistoni F; Dicuonzo G; Rocci L; Rosaria VM; Gebbia N; Tonini G
Pharmacogenomics; 2007 Apr; 8(4):319-27. PubMed ID: 17391070
[TBL] [Abstract][Full Text] [Related]
30. [What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].
Tournigand C; Bengrine-Lefevre L
Rev Med Interne; 2009 May; 30(5):411-5. PubMed ID: 19231039
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab plus irinotecan in refractory colorectal cancer patients.
Gil Delgado M; Spano JP; Khayat D
Expert Rev Anticancer Ther; 2007 Apr; 7(4):407-13. PubMed ID: 17428161
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
33. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
Halama N; Herrmann C; Jaeger D; Herrmann T
Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
[TBL] [Abstract][Full Text] [Related]
34. New treatment options for colorectal cancer.
Erlichman C; Sargent DJ
N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
[No Abstract] [Full Text] [Related]
35. Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab.
Klein B; Gottfried M
J BUON; 2007 Sep; 12 Suppl 1():S127-36. PubMed ID: 17935270
[TBL] [Abstract][Full Text] [Related]
36. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
[TBL] [Abstract][Full Text] [Related]
38. [Transition of chemotherapy for metastatic colorectal cancer and recent advances].
Muro K
Nihon Rinsho; 2010 Jun; 68(6):1143-9. PubMed ID: 20535969
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]